alscarmuzza
Established Member
- Reaction score
- 127
Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia.
Authors:
Elmaadawi IH; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Mohamed BM; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Ibrahim ZAS; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Abdou SM; b Department of Clinical Pathology , Faculty of Medicine, Tanta University , Tanta , Egypt.
El Attar YA; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Youssef A; b Department of Clinical Pathology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Shamloula MM; c Department of Pathology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Taha A; d Department of Internal Medicine, Faculty of Medicine , Tanta University , Tanta , Egypt.
Metwally HG; e Department Clinical Pathology, Faculty of Medicine , Cairo University , Cairo , Egypt.
El Afandy MM; f Department of Anathesia and Intensive Care, Faculty of Medicine , Tanta University , Tanta , Egypt.
Salem ML; g Department of Zoology, Immunology and Biotechnology Unit, Faculty of Science , Center of Excellence in Cancer Research, Tanta University , Tanta , Egypt.
Source:
The Journal Of Dermatological Treatment [J Dermatolog Treat] 2018 Mar 06, pp. 1-10. Date of Electronic Publication: 2018 Mar 06.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat
Imprint Name(s):
Publication: London : Informa Healthcare
Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]-
Abstract:
Background: Management of alopecia areata (AA) and androgenetic alopecia (Androgenetic Alopecia) is often challenging as patients may be resistant to currently available modalities of treatment. The use of stem cells may be a novel option for resistant cases.
Objective: To evaluate the safety and efficacy of the use of autologous bone marrow derived mononuclear cells (including stem cells) as compared to follicular stems cells for the management of resistant cases of AA and Androgenetic Alopecia.
Methods: This study included 40 patients (20 AA patients and 20 Androgenetic Alopecia patients), all patients were treated with a single session of intradermal injection of autologous stem cells (SCs) therapy. They were divided into four groups according to the applied modality [either autologous bone marrow derived mononuclear cells (bone marrow mononuclear cells [BMMCs] or autologous follicular stem cells [FSC]).
Results: Six months after stem cell therapy (SCT) injection, there was a significant improvement, confirmed by immunostaining and digital dermoscopy. The mean improvement in all groups was "very good". There was no significant difference between both methods in either type of alopecia. No serious adverse events were reported.
Conclusion: Autologous BMMCs and FSC seem to be a safe tolerable and effective treatment for the management of both resistant AA and Androgenetic Alopecia.
Contributed Indexing:
Keywords: Bone marrow mononuclear cells; alopecia areata; androgenetic alopecia; digital dermoscopy-CK 15-CD34-CD200; follicular stem cells
Entry Date(s):
Latest Revision: 20180306
Update Code:
20180306
DOI:
10.1080/09546634.2016.1227419
PMID:
27553744
Authors:
Elmaadawi IH; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Mohamed BM; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Ibrahim ZAS; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Abdou SM; b Department of Clinical Pathology , Faculty of Medicine, Tanta University , Tanta , Egypt.
El Attar YA; a Department of Dematology and Venereology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Youssef A; b Department of Clinical Pathology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Shamloula MM; c Department of Pathology , Faculty of Medicine, Tanta University , Tanta , Egypt.
Taha A; d Department of Internal Medicine, Faculty of Medicine , Tanta University , Tanta , Egypt.
Metwally HG; e Department Clinical Pathology, Faculty of Medicine , Cairo University , Cairo , Egypt.
El Afandy MM; f Department of Anathesia and Intensive Care, Faculty of Medicine , Tanta University , Tanta , Egypt.
Salem ML; g Department of Zoology, Immunology and Biotechnology Unit, Faculty of Science , Center of Excellence in Cancer Research, Tanta University , Tanta , Egypt.
Source:
The Journal Of Dermatological Treatment [J Dermatolog Treat] 2018 Mar 06, pp. 1-10. Date of Electronic Publication: 2018 Mar 06.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat
Imprint Name(s):
Publication: London : Informa Healthcare
Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]-
Abstract:
Background: Management of alopecia areata (AA) and androgenetic alopecia (Androgenetic Alopecia) is often challenging as patients may be resistant to currently available modalities of treatment. The use of stem cells may be a novel option for resistant cases.
Objective: To evaluate the safety and efficacy of the use of autologous bone marrow derived mononuclear cells (including stem cells) as compared to follicular stems cells for the management of resistant cases of AA and Androgenetic Alopecia.
Methods: This study included 40 patients (20 AA patients and 20 Androgenetic Alopecia patients), all patients were treated with a single session of intradermal injection of autologous stem cells (SCs) therapy. They were divided into four groups according to the applied modality [either autologous bone marrow derived mononuclear cells (bone marrow mononuclear cells [BMMCs] or autologous follicular stem cells [FSC]).
Results: Six months after stem cell therapy (SCT) injection, there was a significant improvement, confirmed by immunostaining and digital dermoscopy. The mean improvement in all groups was "very good". There was no significant difference between both methods in either type of alopecia. No serious adverse events were reported.
Conclusion: Autologous BMMCs and FSC seem to be a safe tolerable and effective treatment for the management of both resistant AA and Androgenetic Alopecia.
Contributed Indexing:
Keywords: Bone marrow mononuclear cells; alopecia areata; androgenetic alopecia; digital dermoscopy-CK 15-CD34-CD200; follicular stem cells
Entry Date(s):
Latest Revision: 20180306
Update Code:
20180306
DOI:
10.1080/09546634.2016.1227419
PMID:
27553744
